Biotechnology Last week’s notable announcements included Swiss pharma giant Roche saying it has regenerated a previously dropped compound, tominersen - licensed from Ionis Pharmaceuticals, to develop it for Huntington’s disease. Belgium’s biggest pharma firm UCB announced a takeover bid worth up to $1.9 billion for USA-based Zogenix and its epilepsy drug Fintepla. Biotech firm Altos Labs came out of stealth with some $3 billion in financing and luring GlaxoSmithKline’s research chief Hal Barron to be its chief executive, along with several notables to its team. On the research front, Alnylam Pharmaceuticals presented new data supporting its investigational drug vutrisiran in transthyretin amyloidosis. 23 January 2022